1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. NADPH Oxidase

NADPH Oxidase

NADPH oxidase (NOX) is a transmembrane enzyme that is located in intracellular organelles. NADPH oxidase (NOX) enzymes are membrane-bound proteins that catalyze the conversion of oxygen to superoxide. There are a number of isoforms, NOX1-5 and dual oxidases 1 and 2 (DUOX1-2), which have diverse functions. NOX1, NOX2, NOX4, and NOX5 are expressed in human vascular tissue. NOX1 and NOX2 are regulated by cytosolic components loosely termed as activators or organizers, which are generally recruited to the membrane components following cellular stimuli to assemble an active NOX. Molecular switch from NOX1 to NOX2 in colon cancer cells induces ROS production and subsequently enhances MMP-7 expression by deactivating AMPK. Vascular NOX4 is a multifarious NADPH oxidase. NOX4 is a hydrogen peroxide-generating oxygen sensor.

NADPH Oxidase Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-100965
    Diphenyleneiodonium chloride Inhibitor 99.87%
    Diphenyleneiodonium chloride is a NADPH oxidase (NOX) inhibitor and also functions as a TRPA1 activator with an EC50 of 1 to 3 μM. Diphenyleneiodonium chloride selectively inhibits intracellular reactive oxygen species.
  • HY-18950
    GSK2795039 Inhibitor 98.14%
    GSK2795039 is a NADPH oxidase 2 (NOX2) inhibitor with a mean pIC50 of 6 in different cell-free assays. GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 reduces apoptosis.
  • HY-12298
    Setanaxib Inhibitor 99.43%
    Setanaxib (GKT137831) is a selective NADPH oxidase (NOX1/4) inhibitor with Kis of 140 and 110 nM, respectively.
  • HY-12804
    VAS2870 Inhibitor >98.0%
    VAS2870 is a NADPH oxidase (NOX) inhibitor.
  • HY-15598
    20-HETE Activator
    20-HETE (20-hydroxy Arachidonic Acid) is a CYP450 metabolite and a potent vasoconstrictor. 20-HETE is an endogenous inhibitor of the large-conductance Ca2+-activated K+ channel in renal arterioles. 20-HETE constricts smooth muscles, stimulates smooth muscle proliferation and migration. 20-HETE increases NADPH oxidase, ROS, and NF-κB activity. 20-HETE also inhibits endothelial NO synthase and inhibits apoptosis of pulmonary artery smooth muscle cells.
  • HY-P1435A
    NoxA1ds TFA Inhibitor
    NoxA1ds TFA is a potent and selective NADPH oxidase 1 (NOX1) inhibitor (IC50=20 nM). NoxA1ds TFA exhibits selectivity for NOX1 over NOX2, NOX4, NOX5 and xanthine oxidase. NoxA1ds TFA inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro.
  • HY-100111
    GLX351322 Inhibitor 99.48%
    GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM.
  • HY-12805
    ML171 Inhibitor 99.50%
    ML171 (2-Acetylphenothiazine;2-APT) is a potent and selective NADPH oxidase 1 (Nox1) inhibitor that blocks Nox1-dependent ROS generation, with an IC50 of 0.25 μM in HEK293-Nox1 confirmatory assay.
  • HY-120801
    APX-115 Inhibitor >98.0%
    APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 effectively prevents kidney injury.
  • HY-120801A
    APX-115 free base Inhibitor 99.47%
    APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base effectively prevents kidney injury.
  • HY-12803
    Fulvene-5 Inhibitor
    Fulvene-5 is a potent NADPH oxidase 4 (NOX4) inhibitor with antioxidant properties. Fulvene-5 is a reactive oxygen species (ROS) modifying agent and a potent radioprotector. Fulvene-5 has antitumor activity.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.